Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Drug: Mobocertinib for EGFR Exon 20 insertion NSCLC
Study: Open-label Phase I/II trial (EXCLAIM) EGFR EX20ins+ metastatic NSCLC with >=1 prior line of therapy, platinum-pretreated (n=114) Mobocertinib 160 mg PO daily Efficacy: ORR: 28%, Disease control rate: 78%